Information Provided By: 
Fly News Breaks for July 28, 2015
AGN, TEVA
Jul 28, 2015 | 08:24 EDT
Cowen said Teva's (TEVA) deal for Allergan's (AGN) generics division has solid financial and strategic rationale. The firm also sees additional avenues for capital deployment and believes Teva will hasten value creation for shareholders. Cowen, which said they would be buyers of the shares right here, reiterated an Outperform rating and $100 price target on Teva shares.
News For TEVA;AGN From the Last 2 Days
There are no results for your query TEVA;AGN
